, 2008). Because

IL-1β represents a major pro-inflammatory cytokine involved in the induction of miR-146a (Taganov et al., 2006; Nakasa et al., 2008; Sheedy & O’Neill, 2008), it is possible that expression of miR-146a in astrocytes may represent an attempt to modulate the inflammatory response triggered by this cytokine. Accordingly, recent studies identify miR-146a as a key regulator in a feedback system whereby induction of nuclear factor kappa-B MLN8237 (NFkB) through a myeloid differentiation factor 88 (MyD88)-dependent pathway may upregulate the miR-146a, which in turn could downregulate the levels of two key adapter molecules, IL-1RI-associated protein kinases-1 (IRAK1) and -2, and TNF receptor-associated factor 6 (TRAF6) downstream of TLR and cytokine receptors, reducing the activity of this inflammatory pathway (Taganov et al., 2006; Hou et al., 2009). OSI-906 clinical trial These observations are particularly interesting considering the known proconvulsant action of IL-1β mediated by the IL-1 receptor type 1,

as well as the recently reported role of TLR-signalling pathways in epilepsy (Vezzani et al., 2008; Maroso et al., 2009), and suggest that miR-146a induction could function in fine-tuning the response to cytokines in TLE during epileptogenesis. The upregulation of miR-146a observed in the chronic epileptic phase in the post-SE model of TLE was confirmed in human HS specimens of patients undergoing surgery

for pharmacologically refractory TLE. In situ hybridization analysis of miR-146a in human control hippocampus and HS specimens demonstrated expression in neuronal cells. In contrast (as observed in the post-SE rat hippocampus), the expression in glial cells was detected only in tissue of patients with HS, particularly Nintedanib (BIBF 1120) in regions with prominent gliosis. Expression of the miR-146a was observed in neurons and in reactive astrocytes in HS tissue. Neurons constitute an additional source of pro-inflammatory cytokines (including IL-1β), potentially contributing to the inflammatory pathology observed in TLE (Ravizza et al., 2008). Thus, the neuronal expression of miR-146a may also represent an attempt to regulate this inflammatory pathway. A physiological mechanism of defence against activation of inflammatory pathways during epileptogenesis is represented by induction of inhibitory factors, such as CFH (Boon et al., 2009), an important repressor of inflammatory signalling. This factor inhibits excessive activation of the complement cascade, which is prominently activated in both experimental and human TLE (Aronica et al., 2007). Interestingly, CFH has been identified as a target of miR-146a. For instance, in AD brains, upregulation of miR-146a has been linked to downregulation of CFH (Lukiw et al., 2008).